New insider activity at Prelude Therapeutics ( (PRLD) ) has taken place on March 15, 2025.
CEO Krishna Vaddi has made a significant investment in Prelude Therapeutics by purchasing 97,500 shares of the company’s stock, amounting to a total value of $69,225. This move reflects a strong vote of confidence in the company’s future prospects.
More about Prelude Therapeutics
YTD Price Performance: -43.52%
Average Trading Volume: 369,783
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $47.35M